OVERVIEW

 In-Person and Virtual attendance options are available.

Amyloidosis is an underrecognized condition because it has historically been misconceived to be a rare disease and presents in a myriad of clinical situations in a subtle manner. Recent advances in therapeutics have made it imperative that this condition is recognized and categorized appropriately in a timely manner so that individuals can get access to appropriate care. Due to a systemic nature of amyloid, various subspecialities are on the fore front of battling this disease. The goal of the Conference is to create a faculty panel from various disciplines to engage in the mission to promote awareness and educate attendees on Amyloidosis in a comprehensive manner.

TARGET AUDIENCE

Cardiologists, hematologists, neurologists, nephrologists, pulmonologists, hepatologists, nurse practitioners, nurses, social workers, transplant coordinators, and trainees in these subspecialities

LEARNING OBJECTIVES

Upon completion of this course, the participant should be able to:

• Discuss the two major kinds (AL and TTR) of amyloidosis and appropriate diagnosis and categorization of these kinds.
• Identify how to investigate the various organ involvement in Amyloidosis.
• Discuss the current approved therapies for the two major kinds of amyloidosis (AL and TTR).
• Describe the potential future therapies for both TTR and AL amyloidosis.

ACCREDITATION

• 5.75 AMA PRA Category 1 Credit™

  Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

  Houston Methodist designates this Live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.